Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: An assembly having an electric switching function, comprises a switch device which has associated electric conductors and a movable actuating part, on which a hood member is mounted, and which is provided in a housing comprised by an outer injection-molded body; the hood member has its rim resting on a first injection-molded synthetic material body that fixes and partially encloses the electric conductors, and is sealingly connected to the first injection-molded synthetic material body by means of the outer, second injection-molded synthetic material body that both covers the rim of the hood member and also adjoins the first injection-molded synthetic material body.

Abstract: For a conductor structure component with plastics material injection-molded therearound, a fixing member for electric conductors is inserted, which fixing member is formed by a prefabricated carrier body comprising receptacles for the retention of individual wires as said electric conductors.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: An assembly having an electric switching function, comprises a switch device which has associated electric conductors and a movable actuating part, on which a hood member is mounted, and which is provided in a housing comprised by an outer injection-molded body; the hood member has its rim resting on a first injection-molded synthetic material body that fixes and partially encloses the electric conductors, and is sealingly connected to the first injection-molded synthetic material body by means of the outer, second injection-molded synthetic material body that both covers the rim of the hood member and also adjoins the first injection-molded synthetic material body.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: The invention is relative to a pharmaceutical preparation, especially for oral administration, with at least one active substance and with formulation components influencing the release of active substance, which preparation comprises at least one opiod analgesic as active substance that is formulated proportionally on the one hand for rapid release and on the other hand for delayed release in such a manner that the in vitro release rate from the preparation according to the Ph. Eur. paddle test shows a mean value of above 40% by weight after one hour and that the in vitro release rate shows a mean value that is still below 80% by weight after four hours.

Abstract: The invention is relative to a pharmaceutical preparation, especially for oral administration, with at least one active substance and with formulation components influencing the release of active substance, which preparation comprises at least one opiod analgesic as active substance that is formulated proportionally on the one hand for rapid release and on the other hand for delayed release in such a manner that the in vitro release rate from the preparation according to the Ph. Eur. paddle test shows a mean value of above 40% by weight after one hour and that the in vitro release rate shows a mean value that is still below 80% by weight after four hours.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.

Abstract: The invention concerns an instant oral-release capsule containing an aqueous or aqueous alcoholic solution of nifedipine, containing a polyalkylene glycol and a polyoxyethylene ester component, the amount of the ester component in the solution being sufficient to prevent precipitation of nifedipine in the mouth of a patient after release of the solution from the capsule. Preferably, the ester component is an ethoxylated hydrogenated castor oil Cremophor RH40. The solution may further contain a second glycol component, especially glycerol.

Abstract: Fastening mechanism for a transformer module and a signal generator for mounting at a signal tower.A bottom pan is provided having a multi-use holder, a receptacle for a transformer module, and a holding structure with a cable opening for a signal generator. The pan is mated with a cover forming a terminal space, a terminal block being arranged in this terminal space. The transformer module has catch hooks which are secured to corresponding catch noses in the receptacle. The transformer module comprises a transformer, a rectifier, and a lead. The applied multi-use holder comprises a U-shaped cable channel region communicating with a cable lead-through opening in the side wall of the bottom pan. A cable wind-up structure is provided in the terminal space. The cover is held to the pan by at least one catch nose and one catch tongue that are applied to the bottom pan and that engage into corresponding recesses in the cover.

Abstract: A sintered tricalcium phosphate implant for filling bone cavities and for fixing bone fragments is provided, which comprises a discretely-shaped, porous body, at least one therapeutically-active ingredient impregnated into this porous body and distributed among the pores therein, and at least one coating of predetermined thickness of a biodegradable substance on at least a portion of this porous body, so that the time of absorption of the therapeutically-active ingredient is controlled by the thickness of the biodegradable substance. A process for producing this sintered tricalcium phosphate implant is also provided, along with an implant system for filling bone cavities and for fixing bone fragments in a living body, comprising a number of such tricalcium phosphate bone implants, with discrete coatings of biodegradable substance of predetermined thicknesses over at least some of the porous bodies constituting the tricalcium phosphate bone implants.

Abstract: A circuit arrangement for monitoring the state of signal systems, particularly traffic light systems monitors different signal states as to the admissability or inadmissibility thereof in a simple manner without the necessity of carrying out manual wiring manipulations given a change of the signal conditions in adaptation to changed conditions or given an expansion of the signal system to be monitored. For this purpose, test signals which indicate test signal states are fixed in a memory and are processed with the signals indicating the respectively existing actual signal state of the signal transmitters in at least one microprocessor in such a manner that each signal indicating an actual state is compared with all test signals which are called up step-by-step in succession from the memory.